Supplier News

MHRA has granted a license to Gedeon Richter for Ryeqo to treat moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

SGS’s new Antwerp, Belgium, clinical research site will house both clinical trial patients and good manufacturing practice drug manufacturing, and its Glasgow, UK, biosafety testing site now has increased testing capacity.

The planned expansion will expand the capacity of the Charles River Accelerator and Development Lab (CRADL).

ANGUS’ planned expansion will double its tromethamine buffer production capacity.

Evonik’s LIPEX Flow extruder is a new version of its high-pressure equipment for manufacturing liposomal drug products.

Pharmalex has launched the Biopharma Excellence brand, a new service line that combines the expertise of PharmaLex, ERA Consulting, and Biopharma Excellence.

SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California.

Smiths Detection has confirmed that the Bioflash air sampler can detect Beta, Gamma, Kappa, Delta, and Delta plus variants.

Moderna’s new facility is expected to produce 500 million vaccine doses per year.

New excipients for protein-based drug products reduce viscosity while maintaining protein stability.

Moderna’s new 462,000-ft² science center is expected to be completed by 2023.

The test developed by Luas Diagnostics and Bond Digital uses a smartphone app to enhance a 15-minute COVID-19 immunity test.

Certara’s acquisition of Pinnacle 21 grants them access to their compliance validation software.

Thermo Fisher’s new Swiss facility will initially produce CSL Limited’s recombinant factor IX product Idelvion.

The expansion to SGS’s Poitiers facility in France is expected to improve the company’s drug development capabilities.

In September, Codex DNA released a full-length synthetic genome for the SARS-CoV-2 delta variant, which may accelerate discovery and development of diagnostics and treatments for COVID-19.

The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.

NewAge Industries has completed a plant expansion that added new cleanrooms to its headquarters in Southampton, Pa.

Gyros’ new titer kit identifies adeno-associated virus serotype 9 in vector-based cell and gene therapy manufacturing.

CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.

KSL Biomedical announced their expansion into Canada with the acquisition of Pulse Scientific and the incorporation of KSL Biomedical Canada.

Celltrion Group has been granted approval for regdanvimab (CT-P59) to be used as a treatment for COVID-19 by the Korean Ministry of Food and Drug Safety (MFDS).

The research collaboration between AstraZeneca and VaxEquity aims to discover and develop self-amplifying RNA therapeutics.

AstraZeneca will establish an API manufacturing facility near Dublin, Ireland.

BMG Pharma has signed an agreement with HTL for the development and commercialization of injectable products with sodium hyaluronate lipoate formate.

Apellis Pharmaceuticals has announced the top-line results from two Phase III studies, evaluating intravitreal pegcetacoplan as a treatment for geographic atrophy.

Symbiosis Pharmaceutical Services has successfully completed an on-site inspection, performed by the MHRA, of its expanded facility in Stirling, UK.

SGS has selected the European Centre for Clinical Research Training (ECCRT) for the provision of good manufacturing practice (GMP) training of its pharmacy team.

GeneQuine Biotherapeutics has chosen Exothera to advance the development of its osteoarthritis gene therapy product candidate, GQ-303.